

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028755 A1

(51) International Patent Classification⁷: **A61K 38/21**,
38/19, C07K 14/555, 14/56

(21) International Application Number: PCT/US02/30445

(22) International Filing Date:
24 September 2002 (24.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/326,088 28 September 2001 (28.09.2001) US

(71) Applicant (for all designated States except US): **INTER-
MUNE, INC.** [US/US]; 3280 Bayshore Boulevard, Bris-
bane, CA 94005 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **HSU, Henry, H.**
[US/US]; 370 Robinwood Lane, Hillsborough, CA 94010
(US).

(74) Agent: **BORDEN, Paula, A;** Bozicevic, Field & Francis,
L.L.P., 200 Middlefield Road, Suite 200, Menlo Park, CA
94025 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS

(57) Abstract: The present invention provides methods for treating individuals having a hepatitis C virus (HCV) infection, which individuals have failed to respond to therapy with an IFN- α other than consensus interferon (CIFN), or who, following cessation of therapy with an IFN- α other than CIFN, have suffered relapse. The methods generally involve a treatment regimen comprising administering a first dosing regimen of CIFN, followed by a second dosing regimen of CIFN. Ribavirin is administered with at least the second dosing regimen.



WO 03/028755 A1